Health and wellness company Perrigo Company plc (NYSE:PRGO) reported on Thursday the receipt of approval from the US Food and Drug Administration (FDA) for the over-the-counter use of Nasonex 24HR Allergy (mometasone furoate monohydrate 50mcg).
This approval marks the first branded Rx-to-OTC switch for the company and paves the way for Nasonex to enter the OTC marketplace.
Perrigo expects to begin offering Nasonex 24HR Allergy later this year.
Mometasone furoate, is a steroid medication used to treat certain skin conditions, hay fever and asthma.
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China